The Pyrimethamine Market, estimated at USD 1.28 Bn in 2025, is expected to exhibit a CAGR of 5.6% and reach USD 1.87 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Market Dynamics:
Rising Malaria Cases and Increasing Government Support for R&D
The global malaria burden has continued to increase over the past few years mainly attributed to increasing malaria cases in high burden countries of Africa and Asia Pacific regions. This rising disease prevalence is encouraging governments worldwide to boost funding for malaria treatment and prevention strategies. Additionally, major market players are receiving sizeable grants from global health organizations to develop innovative and affordable pyrimethamine-based drugs. For instance, in 2021, Medicines for Malaria Venture received over USD 50 million funding from UNITAID to develop a single-dose curative therapy using pyrimethamine. This rising government support for malaria R&D is expected to drive the demand for pyrimethamine over the forecast period.
Increasing prevalence of malaria worldwide
The increasing prevalence of malaria globally is a major driver for the pyrimethamine market. According to the World Health Organization (WHO), in 2019, there were 229 million recorded cases of malaria around the world, with 409,000 deaths from the disease. Sub-Saharan Africa alone accounted for about 93% of all malaria cases and 94% of all malaria deaths. Pyrimethamine is commonly used in combination with sulfadoxine for the treatment of malaria. As long as malaria remains endemic in many tropical and subtropical regions, the demand for anti-malarial drugs like pyrimethamine will continue to grow. Various government and non-government organizations are working to control the spread of the disease, but its high transmission rate ensures a steady market for pyrimethamine.
Growing focus on effective combination therapies
Combination therapies have become the standard of care for malaria treatment to reduce the risk of drug resistance. Pyrimethamine is most often used in fixed-dose combination with sulfadoxine known as Fansidar or SP. The strong efficacy and safety profile of this combination has made it one of the most widely used anti-malarial regimens globally. Regulatory authorities and health agencies are promoting the use of combination therapies to delay resistance. This growing focus on combination anti-malarials rather than monotherapies is another important driver for the pyrimethamine market.
Increasing resistance to anti-malarial drugs
The development of resistance in malaria parasites is a major challenge faced by the industry. Resistance to pyrimethamine has already been reported in many endemic areas, compromising its efficacy. The widespread irrational use and under-dosing of anti-malarials have significantly contributed to the growing resistance. Once resistance emerges, the demand and sales of the affected drug decline rapidly. Continued monitoring is needed to track the emergence and spread of resistance. Since malaria parasites can develop resistance very quickly, this remains a key restraint on the long-term growth prospects of the pyrimethamine market.